Baseline characteristics and follow-up
Characteristic . | Cohort 1 . | Cohort 2 . | Total . | |||
---|---|---|---|---|---|---|
No. . | % . | No. . | % . | No. . | % . | |
No. of patients | 105 | 105 | 210 | |||
Age, years | ||||||
Median | 48 | 49 | 48.5 | |||
Range | 16-81 | 17-79 | 16-81 | |||
Female | 51 | 49 | 41 | 39 | 92 | 44 |
Follow-up, months | ||||||
Median | 50 | 32 | 40 | |||
Range | 40-65 | 24-40 | 24-65 | |||
Sokal risk score | ||||||
High | 23 | 14 | 19 | |||
Intermediate | 32 | 30 | 31 | |||
Low | 41 | 50 | 46 | |||
Unknown | 4 | 5 | 5 |
Characteristic . | Cohort 1 . | Cohort 2 . | Total . | |||
---|---|---|---|---|---|---|
No. . | % . | No. . | % . | No. . | % . | |
No. of patients | 105 | 105 | 210 | |||
Age, years | ||||||
Median | 48 | 49 | 48.5 | |||
Range | 16-81 | 17-79 | 16-81 | |||
Female | 51 | 49 | 41 | 39 | 92 | 44 |
Follow-up, months | ||||||
Median | 50 | 32 | 40 | |||
Range | 40-65 | 24-40 | 24-65 | |||
Sokal risk score | ||||||
High | 23 | 14 | 19 | |||
Intermediate | 32 | 30 | 31 | |||
Low | 41 | 50 | 46 | |||
Unknown | 4 | 5 | 5 |